Navigation Links
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Date:10/18/2011

RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 20389876.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 25, 2011 to midnight ET on November 1, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 20389876.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of ZFP Therapeutics®, novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
2. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
3. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
5. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sangamo Announces Public Offering of Common Stock
9. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
10. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DALLAS , September 29, 2014 /PRNewswire/ ... market research report "Epigenetics Market by Product (Modifying ... Consumables, Kit, Bisulphite Conversion Kit, Reagents), by ... User - Global Forecast to 2019", published ... the major drivers, restraints, opportunities, current market ...
(Date:9/29/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, is ... to Chairman of the Board of Directors of ... continue to serve as a Director on the Board ... "We are very pleased to have ...
(Date:9/29/2014)... , Sept. 29, 2014  Perrigo Company plc ... that it has transferred a portfolio of preclinical ... 2013 acquisition of Elan Corporation plc, to drug ... of the agreement, Perrigo will receive an upfront ... and royalties on any future sales derived from ...
(Date:9/28/2014)... Boston, Mass. (PRWEB) September 29, 2014 ... delivers integrated cold chain management solutions for highly ... Brian Brazill, will present the company’s Advantage Transport ... Chain GDP & Temperature Management Logistics Global Forum ... will explain and demonstrate the company’s lab software ...
Breaking Biology Technology:Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4SQI Diagnostics Announces New Chairman of Board of Directors 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... PARSIPPANY, N.J., Sept. 1, 2011 New data, published ... the long-term safety and tolerability of FIRMAGON ® ... cancer when used over three years.(1) The new study ... III study (CS21) in which FIRMAGON ® was ...
... BRUSSELS, September 1, 2011 The current ... successful research into blood-related diseases must ensure the safety ... This was a key message of a ... by the European Parliament and attended by doctors, researchers, ...
... September 1, 2011 The medical imaging ... has secured an order for their magnetic resonance imaging ... The software will be used in clinical practice to ... The software, SyMRI Diagnostics, includes tools to automatically ...
Cached Biology Technology:New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 2New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 3New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 4New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 5New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 6Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3
(Date:9/29/2014)... President Juan Manuel Santos has presented Dr. Cristin ... Society, with the prestigious Order of San Carlos. ... citizens, foreign civilians and military officers who have ... the field of international relations. , An international ... Samper was invited to the Colombian Residence in ...
(Date:9/29/2014)... deemed inaccessible or esoteric. Yet in the modern world, ... daily lives and a decisive role in the discovery ... scenes. , UC Santa Barbara,s Paul Atzberger, a professor ... of mechanical engineering, often works in areas where science ... in the Proceedings of the National Academy of ...
(Date:9/29/2014)... a real-time feedback system together with a human energy ... reduction of 37% in energy consumption when compared to ... equivalent to a reduction of 713.71 kg of CO ... another eight halls, exposed only to the real-time feedback ... 3.5% reduction in energy consumption. , Student,s energy-use behaviour ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... for the planet,s gravest health threats is hatched by ... new report sets out a 10-point plan for this ... flu. Ministers of health and agriculture will formulate ... the threat of avian flu and other emerging infectious ...
... Integrates with,Citrix Password Manager Single-Sign On Solution ... Oct. 22 Fujitsu Computer Products of,America, ... products including,hard disk drives, peripherals and biometric ... has been verified as Citrix,Ready(TM). The PalmSecure ...
... The leading cause of death in all cancer patients ... a form of treatment in which chemicals are used to ... biochemists that focuses on cancer cells reports that ingesting apigenin ... fruit improves cancer cells, response to chemotherapy. ...
Cached Biology News:Avian flu threat: New approach needed 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 3Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 4How eating fruit and vegetables can improve cancer patients' response to chemotherapy 2
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Biology Products: